

Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-May-2018
 Document Type: USP Monographs
 DocId: GUID-D6A075E7-C37C-4057-8A9D-9727B68911DC_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M69660_03_01
 DOI Ref: 00t1z

© 2025 USPC
 Do not distribute

Prochlorperazine Edisylate Injection

DEFINITION

Prochlorperazine Edisylate Injection is a sterile solution of Prochlorperazine Edisylate in Water for Injection. It contains an amount of prochlorperazine edisylate equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of prochlorperazine ($C_{20}H_{24}ClN_3S$).

[NOTE—Throughout the following procedures, protect the sample, the Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware.]

IDENTIFICATION

• **A. IDENTIFICATION—ORGANIC NITROGENOUS BASES (181):** Meets the requirements when [USP Prochlorperazine Maleate RS](#) is used as the standard for comparison

ASSAY

• PROCEDURE

Buffer: 2.68 g/L of dibasic sodium phosphate heptahydrate in water, adjusted with phosphoric acid to a pH of 3.0

Mobile phase: Acetonitrile and *Buffer* (7:3)

Standard solution: Equivalent to 0.1 mg/mL of prochlorperazine, from [USP Prochlorperazine Maleate RS](#) in *Mobile phase*

Sample solution: Transfer a portion of Injection, equivalent to 10 mg of prochlorperazine, to a 100-mL volumetric flask, and dilute with *Mobile phase* to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm × 30-cm; packing L1

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 10 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Column efficiency: NLT 3000 theoretical plates

Tailing factor: NMT 2.5

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of prochlorperazine ($C_{20}H_{24}ClN_3S$) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of prochlorperazine in the *Standard solution* (mg/mL)

C_U = nominal concentration of prochlorperazine in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **BACTERIAL ENDOTOXINS TEST (85):** NMT 17.9 USP Endotoxin Units/mg of prochlorperazine
- **pH (791):** 4.2–6.2
- **OTHER REQUIREMENTS:** It meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose or in multiple-dose containers, preferably of Type I glass, protected from light.
- **USP REFERENCE STANDARDS (11):**
[USP Prochlorperazine Maleate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PROCHLORPERAZINE EDISYLATE INJECTION	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-D6A075E7-C37C-4057-8A9D-9727B68911DC_3_en-US

Previous DocID: GUID-D6A075E7-C37C-4057-8A9D-9727B68911DC_1_en-US

DOI: https://doi.org/10.31003/USPNF_M69660_03_01

DOI ref: [00t1z](#)

OFFICIAL